A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Male and female subjects aged 18-65 years, inclusive
• BMI \>18 and \<40
• Minimum affected BSA of 10%
• PASI score ≥ 12
• PGA ≥ 3
• Diagnosed with moderate-to-severe plaque psoriasis
Locations
United States
Arizona
Vanda Investigational Site
RECRUITING
Glendale
California
Vanda Investigational Site
RECRUITING
Fremont
New York
Vanda Investigational Site
RECRUITING
Rochester
Washington
Vanda Investigational Site
RECRUITING
Spokane
Contact Information
Primary
Vanda Pharmaceuticals, Inc.
clinicaltrials@vandapharma.com
202-734-3400
Time Frame
Start Date: 2026-02-17
Estimated Completion Date: 2028-12
Participants
Target number of participants: 300
Treatments
Experimental: Ponesimod
Ponesimod
Related Therapeutic Areas
Sponsors
Leads: Vanda Pharmaceuticals